Health & Medicinearticle2026-08-04

Development a novel in silico mRNA vaccine against Clostridium difficile

Open access0 citations

Abstract

Clostridium difficile , a toxin-producing bacterium, can lead to conditions ranging from mild diarrhea to severe pseudomembranous colitis. Our research introduces an innovative strategy for developing a multi-epitope mRNA vaccine using in-silico methods targeting proteins involved in Clostridium difficile infection (CDI). Through computational models, we identified epitopes for B cells, helper T lymphocytes (HTL), and cytotoxic T lymphocytes (CTL) from protein sequences, assessing their immune response potential, allergenicity, toxicity, and autoimmune risk. The constructed 3D model underwent interaction docking and immune simulations, including evaluations of population coverage and physicochemical properties. Finally, molecular dynamics simulations were employed to test the vaccine's stability. Our findings suggest that this approach holds promise for creating a multi-epitope mRNA vaccine against C. difficile infection.

// Source

View paper (DOI)Open access versionOpenAlexJournal of Genetic Engineering and BiotechnologyPublished 2026-08-04

Authors: Nasim Cheraghi, Saeed Khoshnood, Parisa Asadollahi, Faezeh Sojoudi Ghamnak, Maryam Asadinezhad, Hedayat Heydarizadeh, Nazanin Omidi, Behrooz Sadeghi Kalani

Institutions: Ilam University, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Medical University of Ilam